Megaphone icon ETF Database is now VettaFi. Read More >
ETFdb Logo
ETFdb Logo
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • Entrepreneur ETF
    • Equity ETF
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Future ETFs
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Modern Alpha
    • Multi-Asset
    • Multi-Factor
    • Nasdaq Investment Intelligence
    • Portfolio Strategies
    • Retirement Income
    • Smart Beta
    • Thematic Investing
    • Volatility Resource
  • Database
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
    • ETFs Future-Forward 2021: An iShares Investing Symposium
    • Three Themes for 2021: An iShares & MSCI Investing Symposium
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Videos & Podcasts
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. A Targeted ETF to Capture M&A, Consolidation in the Biotech Space
News
Share

A Targeted ETF to Capture M&A, Consolidation in the Biotech Space

Max ChenApr 10, 2019
2019-04-10

The biotechnology space is filled with new drug makers and treatments that help make lives better, and large pharma has typically tapped into these smaller innovators to fill out their own businesses. With increased merger and acquisition activity in the biotech sector, ETF investors may look to targeted plays to capture the up-and-coming companies.

“We’ve had a lot of activity in the M&A side – mergers and acquisitions, huge deals, which really have driven valuations across the whole space,” Andy Hicks, SVP, Director of Portfolio Management & Research, ALPS, said at Inside ETFs.

As a way to gain exposure to these smaller treatment developers, ETF investors can look to something like the ALPS Medical Breakthroughs ETF (SBIO ), which focuses on small- and mid-cap companies that have one or more drugs in either Phase II or Phase III trials.

Biotech ETFs that focus on smaller companies have been enjoying a nice boost this year as larger companies begin to sift through smaller researchers to build up their portfolios.

Many big pharmaceutical and biotechnology companies are no longer relying on blockbuster drug sales as many of their intellectual property rights expire. Instead, many are now relying on targeted or specialized therapies or treatment methods, which has increased the demand for mergers and acquisitions for smaller developers and research companies.

Consequently, investors may turn to targeted plays like the SBIO, which invests in stocks of mid-cap and small-cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the Poliwogg Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.

The component holdings have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. In a Phase II trial, the drug is administered to a group of 100-300 people to see if it is effective and to evaluate its safety. In a Phase III trial, the drug is given to a larger group, between 500-3,000 people, to confirm its effectiveness, monitor side effects, compare it to commonly used treatments and collect information that will allow the drug or treatment to be used safely.

Watch the full interview between ETF Trends CEO Tom Lydon and Andy Hicks


Content continues below advertisement

For more ETF-related commentary from Tom Lydon and other industry experts, visit our video category on our sister site, ETFtrends.com.

» Popular Pages

  • Tickers
  • Articles

May 24

Revisiting Energy Exposure? Tailor Your Approach

May 24

ETF Prime: VettaFi, Equity ETFs, Markets, and Investing

May 24

Coinbase Becomes First Crypto Company in Fortune 500

May 24

Grab a Slice of This ETF for Climate Transition Leaders

May 24

The Double-Edged Sword of Women's Long-Term Care

May 24

How to Remove Investment Bias in Shifting Markets

May 24

Morningstar Report Shows Power of Active Management

May 24

Sectors Matter In U.S. High Yield

May 24

REITS Could Outperform Private Equity Real Estate

May 24

S&P 500 Bulls Show Some Life, but Bears Stay Ahead

QQQ

Invesco QQQ Trust

SPY

SPDR S&P 500 ETF Trust

VOO

Vanguard S&P 500 ETF

VTI

Vanguard Total Stock Market...

SCHD

Schwab US Dividend Equity ETF...

XLE

Energy Select Sector SPDR...

DBA

Invesco DB Agriculture Fund

VGT

Vanguard Information...

WEAT

Teucrium Wheat Fund

ARKK

ARK Innovation ETF


Content continues below advertisement

Loading Articles...
Help & Info
  • Contact Us
  • Mission Statement
  • Press
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © ETF Flows LLC
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

Equity ETF Channel

Retirement Portfolio Redux: Is the 60%-40% Portfolio Dead?

Debbie CarlsonOct 22, 2020
2020-10-22

With the 10-year U.S. Treasury yield hovering below 1% and Federal Reserve Chairman Jerome Powell...

Equity ETF Channel

Portfolio Diversification Isn't Dead, It Was Just Sleeping

Debbie CarlsonOct 15, 2020
2020-10-15

Investors could be forgiven to think there was no reason to invest outside of the U.S. for the...

}
X